Strengthening Research into Adhesives, Transdermal Absorption and Environmental Technologies
First written in FY2016. 17 of 25 entries say "Restated". Latest entry: FY2026.
63 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses amounted to ¥1,560 million for the fiscal year.」
R&D expenses amounted to ¥1,560 million, and multiple new products were launched in both the Medical and Tape businesses. - FY2024-Q2RestatedAnnual report
「Group-wide research and development activities amounted to ¥604 million during the six-month period ended [second quarter]. There were no material changes in the status of the Group's research and development activities during the six-month period ended [second quarter].」
The Company stated that there were no material changes in research and development activities and recorded R&D expenses of ¥604 million for the six-month period. - FY2024-Q1RestatedAnnual report
「Group-wide research and development activities amounted to ¥291 million during the three-month period ended [first quarter]. There were no material changes in the status of the Group's research and development activities during the three-month period ended [first quarter].」
The Company stated that there were no material changes in research and development activities and recorded R&D expenses of ¥291 million for the three-month period. - FY2022AdvancedAnnual report
「R&D expenses amounted to ¥1,057 million for the fiscal year.」
The Group is reorganizing its R&D organization and collaborating with startup companies, and has launched multiple new products in both the Medical and Tape businesses. - FY2022-Q3RestatedAnnual report
「Group-wide research and development activities amounted to ¥861 million during the nine-month period ended [third quarter]. There were no material changes in the status of the Group's research and development activities during the nine-month period ended [third quarter].」
The Company stated that there were no material changes in research and development activities and reported R&D expenses of ¥861 million for the nine-month period. - FY2022-Q2RestatedAnnual report
「Group-wide research and development activities amounted to ¥578 million during the six-month period ended [second quarter]. There were no material changes in the status of the Group's research and development activities during the six-month period ended [second quarter].」
The Company stated that there were no material changes in research and development activities and reported R&D expenses of ¥578 million for the six-month period. - FY2021AdvancedAnnual report
「R&D expenses amounted to ¥1,064 million for the fiscal year.」
The Group is reorganizing its R&D organization, advancing collaboration programs with startup companies and proposal activities addressing customer issues, and has launched 5 Medical products and 4 Tape products. - FY2021-Q3RestatedAnnual report
「Group-wide research and development activities amounted to ¥774 million during the nine-month period ended [third quarter]. There were no material changes in the status of the Group's research and development activities during the nine-month period ended [third quarter].」
R&D expenses amounted to ¥774 million for the nine-month period, with no material changes in the status of research and development activities. - FY2021-Q1RestatedAnnual report
「Group-wide research and development activities amounted to ¥255 million during the three-month period ended [first quarter]. There were no material changes in the status of the Group's research and development activities during the three-month period ended [first quarter].」
Records R&D expenses of ¥255 million and states that there have been no material changes in the status of R&D activities. - FY2020ReframedAnnual report
「The TDS Promotion Unit, which promotes development planning for new transdermal patch products, and the TRD Promotion Unit, which promotes the development and cultivation of new products in the Tape business, were placed under the Research and Development Division, strengthening the development framework to achieve the goals of ISHIZUE 2023.」
The promotion units changed from organizations directly under senior management to units under the Research and Development Division, and the research and development framework was reorganized for ISHIZUE 2023. - FY2020-Q3RestatedAnnual report
「Group-wide research and development activities amounted to ¥798 million during the nine-month period ended [third quarter]. There were no material changes in the status of the Group's research and development activities during the nine-month period ended [third quarter].」
R&D expenses amounted to ¥798 million for the nine-month period, with no material changes in the status of research and development activities. - FY2020-Q2RestatedAnnual report
「Group-wide research and development activities amounted to ¥535 million during the six-month period ended [second quarter]. There were no material changes in the status of the Group's research and development activities during the six-month period ended [second quarter].」
R&D expenses amounted to ¥535 million for the six-month period, with no material changes in the status of research and development activities. - FY2020-Q1RestatedAnnual report
「Group-wide research and development activities amounted to ¥268 million during the three-month period ended [first quarter]. There were no material changes in the status of the Group's research and development activities during the three-month period ended [first quarter].」
R&D expenses of ¥268 million were recorded, with no material changes in research and development activities. - FY2019AdvancedAnnual report
「The TDS Promotion Unit, which promotes development planning for new transdermal patch products, and the TRD Promotion Unit, which promotes the development and cultivation of new products in the Tape business, were newly established as organizations directly under senior management. The Group will strengthen its development framework to achieve the goals of the new medium-term management plan, ISHIZUE 2023 — SHINKA: Transformation.」
Two promotion units responsible for transdermal patches and new Tape products were newly established directly under senior management, strengthening the development framework. - FY2019-Q3RestatedAnnual report
「Group-wide research and development activities amounted to ¥884 million during the nine-month period ended [third quarter]. There were no material changes in the status of the Group's research and development activities during the nine-month period ended [third quarter].」
R&D expenses amounted to ¥884 million for the nine-month period, with no material changes in the status of research and development activities. - FY2019-Q2RestatedAnnual report
「Group-wide research and development activities amounted to ¥603 million during the six-month period ended [second quarter]. There were no material changes in the status of the Group's research and development activities during the six-month period ended [second quarter].」
R&D expenses of ¥603 million were recorded, with no material changes in the status of research and development activities. - FY2019-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the consolidated fiscal year was ¥284 million. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
R&D expenses amounted to ¥284 million for the quarter, with no material changes in research and development activities. - FY2018AdvancedAnnual report
「The Group will strengthen its basic research framework, centered on the Advanced Applied Research Institute, established in August 2017 as the successor to the former Central Research Institute, focusing on research into adhesives with new value-added features, further development of transdermal absorption technologies, and technological development aimed at reducing environmental impact.」
The research framework following the establishment of the Advanced Applied Research Institute was specified, and R&D expenses also increased to ¥1,241 million. - FY2018-Q2RestatedAnnual report
「Group-wide research and development activities amounted to ¥627 million during the six-month period ended [second quarter]. There were no material changes in the status of the Group's research and development activities during the six-month period ended [second quarter].」
The Company recorded ¥627 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「Group-wide research and development activities amounted to ¥283 million during the three-month period ended [first quarter]. There were no material changes in the status of the Group's research and development activities during the three-month period ended [first quarter].」
R&D expenses amounted to ¥283 million for the quarter, with no material changes in the status of research and development activities. - FY2017AdvancedAnnual report
「R&D expenses amounted to ¥1,153 million for the fiscal year, and the Group will actively pursue efforts to create new materials and technologies and develop high-value-added products that support growth.」
R&D expenses of ¥1,153 million were recorded, and multiple new products were launched in both the Medical and Tape businesses. - FY2017-Q3RestatedAnnual report
「Group-wide research and development activities amounted to ¥837 million during the nine-month period ended [third quarter]. There were no material changes in the status of the Group's research and development activities during the nine-month period ended [third quarter].」
R&D expenses amounted to ¥837 million, with no material changes in the status of research and development activities. - FY2017-Q2RestatedAnnual report
「Group-wide research and development expenses for the second quarter consolidated cumulative period were ¥567 million. There were no material changes in the status of the group’s research and development activities during the second quarter consolidated cumulative period.」
Research and development expenses were ¥567 million, and the company stated that there were no material changes in its research and development activities. - FY2017-Q1RestatedAnnual report
「Group-wide research and development expenses for the first quarter consolidated cumulative period were ¥257 million. There were no material changes in the status of the group’s research and development activities during the first quarter consolidated cumulative period.」
Quarterly research and development expenses were ¥257 million, and the company stated that there were no material changes in its research and development activities. - FY2016First statedAnnual report
「We will strengthen our basic research capabilities, focusing on research into adhesives with new added value, further development of transdermal absorption technologies, and applications of environmentally friendly technologies.」
Research and development expenses were ¥1,108 million, with the aim of creating new materials, new technologies and high-value-added products.